Godehard Oepen, MD
Psychiatry · Birmingham, ALNPI 1508811597
Payments from drug & device makers
Across 842 payments — averaging $612.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$190K
- Teva Pharmaceuticals USA, Inc.$117K
- Otsuka America Pharmaceutical, Inc.$72K
- Axsome Therapeutics, Inc.$59K
- Alkermes, Inc.$46K
- Takeda Pharmaceuticals U.S.A., Inc.$18K
- plus $14K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 276 | $190,343 |
| Teva Pharmaceuticals USA, Inc. | 152 | $117,181 |
| Otsuka America Pharmaceutical, Inc. | 100 | $71,602 |
| Axsome Therapeutics, Inc. | 56 | $58,627 |
| Alkermes, Inc. | 69 | $46,476 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $18,087 |
| Vanda Pharmaceuticals Inc. | 13 | $9,370 |
| Johnson & Johnson | 26 | $1,003 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 44 | $897 |
| Supernus Pharmaceuticals, Inc. | 5 | $583 |
| Lundbeck LLC | 14 | $313 |
| Neurocrine Biosciences, Inc. | 6 | $235 |
| Jazz Pharmaceuticals Inc. | 5 | $201 |
| Avanir Pharmaceuticals, Inc. | 5 | $196 |
| Sunovion Pharmaceuticals Inc. | 14 | $154 |
| Bausch Health US, LLC | 6 | $103 |
| Neuronetics, Inc. | 1 | $102 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $84 |
| Almatica Pharma LLC | 4 | $83 |
| Eisai Inc. | 5 | $69 |
| Indivior Inc. | 2 | $49 |
| Merck | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $21 |
| Adlon Therapeutics L.p. | 1 | $19 |
| Neos Therapeutics, LP | 1 | $15 |
How this compares
$515,834 in reported general payments places this provider in the 95th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Birmingham
- Matthew MacalusoBirmingham$2.8M
- Richard SheltonBirmingham$2.4M
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Melissa KarrhBirmingham$51K
- Santosh PillaiBirmingham$39K
- Jennifer HadleyBirmingham$27K
- Kerry ClearyBirmingham$12K
- Praveen JettyBirmingham$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.